Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1442-2042.2006.01679.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relative fat mass is a valuable predictor of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males: clinical implications.
Transl Androl Urol
December 2024
Department of Urology and Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Background: The global prevalence of lower urinary tract symptoms suggestive of benign prostate hyperplasia (LUTS/BPH) escalates, with obesity recognized as a major contributing factor. However, the association between the relative fat mass (RFM) and LUTS/BPH remains unexplored. This 7-year follow-up study aimed to investigate the cross-sectional and longitudinal relationships between RFM and LUTS/BPH.
View Article and Find Full Text PDFTrends in Immunotherapy (IO) Use and Survival Among Patients With High-Incidence Stage IV Cancers Across the United States.
J Surg Oncol
January 2025
Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background And Objectives: IO has transformed cancer management, but its adoption in advanced cancer patients varies by tumor type. With more Stage IV patients undergoing surgery, understanding site-specific outcomes in these challenging patients is essential. We aimed to evaluate IO use and survival trends for Stage IV cancer patients across high-incidence cancers in the US.
View Article and Find Full Text PDFIncidence, trends and patterns of female breast, cervical, colorectal and prostate cancers in Antigua and Barbuda, 2017-2021: a retrospective study.
BMC Cancer
January 2025
Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu- Natal, Durban, South Africa.
Background: Globally, estimates of cancer cases and deaths have increased since 2018, particularly in Latin America and Caribbean countries. In Antigua and Barbuda, understanding the burden of common cancers such as female breast, cervical, colorectal and prostate cancers is critical. This study aimed to assess the incidence, trends, and patterns of these four cancers from 2017 to 2021.
View Article and Find Full Text PDFA plant-based diet index and all-cause and cause-specific mortality: a prospective study.
Food Funct
January 2025
Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
: A plant-based dietary pattern has been recently suggested to have health benefits. However, its relationship with mortality is not completely consistent in prior studies. We aimed to investigate whether a plant-based diet was associated with a lower death risk in a Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening study.
View Article and Find Full Text PDFSynergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer.
Am J Cancer Res
December 2024
Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University Providence, RI 02903, USA.
Androgen receptor (AR) signaling is a target in prostate cancer therapy and can be treated with non-steroidal anti-androgens (NSAA) including enzalutamide, and apalutamide for patients with advanced disease. Metastatic castration-resistant prostate cancer (mCPRC) develop resistance becomes refractory to therapy limiting patient overall survival. Darolutamide is a novel next-generation androgen receptor-signaling inhibitor that is FDA approved for non-metastatic castration resistant prostate cancer (nmCRPC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!